BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20223111)

  • 1. [Detection of multiple gene mutations in non-small-cell lung cancer by suspension microarray].
    Wang D; Ye YK; Su CQ; Rong TH; Guo AY; Yi JH; Liu YJ
    Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(48):3393-6. PubMed ID: 20223111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined detection of p53, p16, Rb, and EGFR mutations in lung cancer by suspension microarray.
    Ye Y; Wang D; Su C; Rong T; Guo A
    Genet Mol Res; 2009 Dec; 8(4):1509-18. PubMed ID: 20082263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
    Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
    Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].
    Zhou CC; Zhou SW; Pan H; Su B; Gao ZQ
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):119-23. PubMed ID: 17645848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy.
    Yamaguchi F; Kugawa S; Tateno H; Kokubu F; Fukuchi K
    Lung Cancer; 2012 Dec; 78(3):201-6. PubMed ID: 23026641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
    Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
    Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
    Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers.
    Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD
    Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
    Mack PC; Gandara DR; Bowen C; Edelman MJ; Paglieroni T; Schnier JB; Gelmann EP; Gumerlock PH
    Clin Cancer Res; 1999 Sep; 5(9):2596-604. PubMed ID: 10499638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer.
    Ahrendt SA; Chow JT; Xu LH; Yang SC; Eisenberger CF; Esteller M; Herman JG; Wu L; Decker PA; Jen J; Sidransky D
    J Natl Cancer Inst; 1999 Feb; 91(4):332-9. PubMed ID: 10050866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual DNA microarray for detection of epidermal growth factor receptor (EGFR) gene mutations.
    Xue L; Fei JJ; Song Y; Xu RH; Bai YJ
    Scand J Clin Lab Invest; 2014 Nov; 74(8):693-9. PubMed ID: 25223598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers.
    Lee YC; Chang YL; Luh SP; Lee JM; Chen JS
    Ann Thorac Surg; 1999 Aug; 68(2):343-7; discussion 348. PubMed ID: 10475393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
    Zhang Y; Xu Y; Wang M
    Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.
    Zhao X; Han RB; Zhao J; Wang J; Yang F; Zhong W; Zhang L; Li LY; Wang MZ
    Respiration; 2013; 85(2):119-25. PubMed ID: 22797485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.